

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

6643


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/415		AI	(11) International Publication Number: WO 98/51304
			(43) International Publication Date: 19 November 1998 (19.11.98)
(21) International Application Number: PCT/US97/21565		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 November 1997 (26.11.97)			
(30) Priority Data: 08/857,811 16 May 1997 (16.05.97) US			
(71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).			
(72) Inventor: CAMDEN, James, Berger; 7339 Charter Cup Lane, West Chester, OH 45069 (US).			
(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).		Published With international search report.	

(54) Title: BENZIMIDAZOLE-2-CARBAMATES FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER

## (57) Abstract

A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can be used to treat viral infections that comprises a fungicide is disclosed. The particular fungicide used is a benzimidazole derivative having formula (I), wherein R is selected from the group consisting of H, carboxyl ( $-\text{CO}_2\text{H}$ ), hydroxyl, amino or esters ( $-\text{CO}_2\text{R}'$ ) wherein R' is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1-8 carbons or  $\text{CH}_3\text{CH}_2(\text{OCH}_2\text{CH}_2)_n-$  or  $\text{CH}_3\text{CH}_2\text{CH}_2(\text{OCH}_2\text{CH}_2\text{CH}_2)_n-$  or  $(\text{CH}_3)_2\text{CH}-(\text{OCH}(\text{CH}_3)\text{CH}_2)_n-$  wherein n is from 1-3, the pharmaceutically acceptable salts thereof, or mixtures thereof.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## BENZIMIDAZOLE-2-CARBAMATES FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER

## TECHNICAL FIELD

This invention is a pharmaceutical composition that is effective in the treatment of HIV and other viral infections and inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains a benzimidazole derivative, the pharmaceutically acceptable salts thereof or mixtures thereof with other viral and cancer treatments.

## BACKGROUND OF THE INVENTION

HIV and other viral infections are one leading cause of death. HIV is a disease in which a virus is replicated in the body which attacks the body's immune system. The HIV virus is not easily destroyed nor is there a good mechanism for keeping the host cells from replicating the virus. Herpes Simplex is another viral infection which is difficult, if not impossible, to cure. A method of treating these diseases and other viral infections is highly desirable. Clearly a material which would target the HIV virus and inhibit viral replication is highly desirable.

Cancers are a leading cause of death in animals and humans. The exact cause of cancer is not known, but links between certain activities such as smoking or exposure to carcinogens and the incidence of certain types of cancers and tumors has been shown by a number of researchers.

Many types of chemotherapeutic agents have been shown to be effective against cancers and tumor cells, but not all types of cancers and tumors respond to these agents. Unfortunately, many of these agents also destroy normal cells. The exact mechanism for the action of these chemotherapeutic agents are not always known.

Despite advances in the field of cancer treatment the leading therapies to date are surgery, radiation and chemotherapy. Chemotherapeutic approaches are said to fight cancers that are metastasized or ones that are particularly aggressive. Such cytotoxic or cytostatic agents work best on cancers with large growth factors, i.e., ones whose cells are rapidly dividing. To date, hormones, in particular estrogen, progesterone and testosterone, and some antibiotics produced by a variety of microbes, alkylating agents, and anti-metabolites form the bulk of therapies available to oncologists. Ideally cytotoxic agents that have specificity for cancer and tumor cells while not affecting normal cells would be extremely desirable. Unfortunately, none have been found and instead agents which target especially rapidly dividing cells (both tumor and normal) have been used.


Clearly, the development of materials that would target tumor cells due to some unique specificity for them would be a breakthrough. Alternatively, materials that were cytotoxic to tumor cells while exerting mild effects on normal cells would be desirable. Therefore, it is an object of this invention to provide a pharmaceutical composition that is effective in inhibiting the growth of tumors and cancers in mammals with mild or no effects on normal cells.

More specifically, it is an object of this invention to provide an anti-cancer composition comprising a pharmaceutical carrier and a benzimidazole derivative as defined herein along with a method for treating such cancers.


These compositions are also effective against viruses and can be used to treat viral infections. Therefore it is another object of this invention to provide a method of treating viral infections such as HIV, influenza and rhinoviruses.

These and other objects will become evident from the following detailed description of this inventions.

A pharmaceutical composition for treatment of viral infections and cancer in mammals, and in particular, warm blooded animals and humans, comprising a pharmaceutical carrier and an effective amount of compound having the formula:




wherein R is selected from the group consisting of H, carboxyl ( $-\text{CO}_2\text{H}$ ), hydroxyl, amino or esters ( $-\text{CO}_2\text{R}'$ ) wherein  $\text{R}'$  is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1 - 8 carbons or  $\text{CH}_3\text{CH}_2(\text{OCH}_2\text{CH}_2)_n-$  or  $\text{CH}_3\text{CH}_2\text{CH}_2(\text{OCH}_2\text{CH}_2\text{CH}_2)_n-$  or  $(\text{CH}_3)_2\text{CH}-$  and





and  $(\text{OCH}(\text{CH}_3)\text{CH}_2)_n-$  wherein n is from 1-3 or the pharmaceutically acceptable inorganic or organic acid salts thereof, or mixtures thereof. The preferred alkyl groups are straight chain. Preferably the halogen is substituted on the terminal carbon, and the halogen is chlorine. The preferred cycloalkyl groups are those having 3-6 carbon atoms. The cycloalkyl groups also include those which are substituted on an alkyl chain, 2-cyclopropylethyl, cyclopropylmethyl, 2-cyclopropyl


propyl or 2-cyclopropylpropyl or cyclohexylmethyl. Preferred compounds are those having the formulas:




and



and



and



These compositions can be used to inhibit the growth of cancers and other tumors in humans or animals by administration of an effective amount either orally, rectally, topically or parenterally, intravenously or by injection into the tumor.

#### DETAILED DESCRIPTION OF THE INVENTION

##### A. Definitions:

As used herein, the term "comprising" means various components can be conjointly employed in the pharmaceutical composition of this invention.

Accordingly, the terms "consisting essentially of" and "consisting of" are embodied in the term comprising.

As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.

As used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.

As used herein, a "pharmaceutical addition salts" is salt of the anti-cancer compound with an organic or inorganic acid. These preferred acid addition salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like.

As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the anti-cancer agent to the animal or human. The carrier may be liquid or solid and is selected with the planned manner of administration in mind.

As used herein, "cancer" refers to all types of cancers or neoplasm or malignant tumors found in mammals, including leukemia.

As used herein, the "anti-cancer compounds" are benzimidazole derivatives, and their salts. The exact benzimidazoles derivatives are described in detail below.

As used herein "chemotherapeutic agents" includes DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others, such as Asparaginase or hydroxyurea.

As used herein, "viruses" includes viruses which cause diseases (viral infection) in man and other warm blooded animals such as HIV virus, herpes, influenza and rhinoviruses.


As used herein "potentiators" are materials such as triprolidine and its cis-isomer and procodazole which are used in combination with the chemotherapeutic agents and herbicidal or fungicidal agents.




As used herein "significantly reduce" means to reduce the mass of the tumor by significant amount. This will usually be to less than 50% of its original mass, and preferably to reduce the mass to non-detectable amounts.

## B. THE ANTI-CANCER AND ANTI-VIRAL COMPOUNDS


The anti-cancer compounds are benzimidazole derivatives. These derivatives have the formula:




wherein R is selected from the group consisting of H, carboxyl ( $-\text{CO}_2\text{H}$ ), hydroxyl, amino or esters ( $-\text{CO}_2\text{R}'$ ) wherein  $\text{R}'$  is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1 - 8 carbons or  $\text{CH}_3\text{CH}_2(\text{OCH}_2\text{CH}_2)_n-$  or  $\text{CH}_3\text{CH}_2\text{CH}_2(\text{OCH}_2\text{CH}_2\text{CH}_2)_n-$  or  $(\text{CH}_3)_2\text{CH}(\text{OCH}(\text{CH}_3)\text{CH}_2)_n-$  wherein n is from 1-3 and the pharmaceutically acceptable organic or inorganic addition salts thereof. The preferred alkyl groups are straight chain. Preferably the halogen is substituted on the terminal carbon, and the halogen is chlorine. The preferred cycloalkyl groups are those having 3-6 carbon atoms. The cycloalkyl groups also include those which are substituted on an alkyl chain, 2-cyclopropylethyl, cyclopropylmethyl, 2-cyclopropylpropyl or 2-cyclopropylpropyl or cyclohexylmethyl. Preferred compounds are those having the formulas:




and




and




and



and



and



### C. HIV DRUGS

HIV is treated with two general classes of drugs, reverse transcriptase inhibitors and protease inhibitors. AZT is widely used to treat acute HIV. The herbicidal and fungicidal agents and their derivatives can be used in conjunction with AZT for the treatment of acute HIV. They do not interfere with the activity of the AZT.

Other HIV and antiviral agents can be used in conjunction with the therapy provided by this invention. These would include reverse transcriptase inhibitors and protease inhibitors. The drugs can be used concurrently or given in sequence with the herbicidal or fungicidal agents.

### D. CHEMOTHERAPEUTIC AGENTS

The fungicides and herbicides can be administered with chemotherapeutic agents. This can be in sequence, where the chemotherapeutic agent is used to debulk the tumor and then the treatment with the herbicide or fungicide begins, or the two materials can be administered together.

The chemotherapeutic agents are generally grouped as DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others such as Asparaginase or hydroxyurea. Each of the groups of chemotherapeutic agents can be further divided by type of activity or compound. The chemotherapeutic agents used in the sequential method in combination herbicidal or

fungicidal agents s primarily include members of the DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents groups. For a detailed discussion of the chemotherapeutic agents and their method of administration, see Dorr, et al. *Cancer Chemotherapy Handbook*, 2d edition, pages 15-34, Appleton & Lange (Connecticut, 1994) herein incorporated by reference.

In order to reduce the mass of the tumor or stop the growth of the cancer cells, the chemotherapeutic agent must prevent the cells from replicating and also must interfere with the cell's ability to maintain itself. The agents which do this are primarily the DNA-interactive agents such as Cisplatin, and tubulin interactive agents.

DNA-Interactive Agents include the alkylating agents, e.g. Cisplatin, Cyclophosphamide, Altretamine; the DNA strand-breakage agents, such as Bleomycin; the intercalating topoisomerase II inhibitors, e.g., Dactinomycin and Doxorubicin); the nonintercalating topoisomerase II inhibitors such as, Etoposide and Teniposide; and the DNA minor groove binder Plcamydin.

The alkylating agents form covalent chemical adducts with cellular DNA, RNA, and protein molecules and with smaller amino acids, glutathione and similar chemicals. Generally, these alkylating agents react with a nucleophilic atom in a cellular constituent, such as an amino, carboxyl, phosphate, sulfhydryl group in nucleic acids, proteins, amino acids, or glutathione. The mechanism and the role of these alkylating agents in cancer therapy is not well understood. Typical alkylating agents include:

- Nitrogen mustards, such as Chlorambucil, Cyclophosphamide, Isofamide, Mechlorethamine, Melphalan, Uracil mustard;
- aziridines such as Thiotepa;
- methanesulfonate esters such as Busulfan;
- nitroso ureas, such as Carmustine, Lomustine, Streptozocin;
- platinum complexes, such as Cisplatin, Carboplatin;
- bioreductive alkylator, such as Mitomycin, and Procarbazine, Dacarbazine and Altretamine;

DNA strand breaking agents include Bleomycin;

DNA topoisomerase II inhibitors include the following:

- Intercalators, such as Amsacrine, Dactinomycin, Daunorubicin, Doxorubicin, Idarubicin, and Mitoxantrone;
- nonintercalators, such as Etoposide and Teniposide.

The DNA minor groove binder is Plcamydin.

The antimetabolites interfere with the production of nucleic acids by one or the other of two major mechanisms. Some of the drugs inhibit production of the deoxyribonucleoside triphosphates that are the immediate precursors for DNA synthesis, thus inhibiting DNA replication. Some of the compounds are sufficiently like purines or pyrimidines to be able to substitute for them in the anabolic nucleotide pathways. These analogs can then be substituted into the DNA and RNA instead of their normal counterparts. The antimetabolites useful herein include:

folate antagonists such as Methotrexate and trimetrexate

pyrimidine antagonists, such as Fluorouracil, Fluorodeoxyuridine, CB3717, Azacytidine, Cytarabine, and Floxuridine

purine antagonists include Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin;

sugar modified analogs include Cytarabine, Fludarabine;

ribonucleotide reductase inhibitors include hydroxyurea.

Tubulin Interactive agents act by binding to specific sites on tubulin, a protein that polymerizes to form cellular microtubules. Microtubules are critical cell structure units. When the interactive agents bind on the protein, the cell can not form microtubules. Tubulin Interactive agents include Vincristine and Vinblastine, both alkaloids and Paclitaxel.

Adrenal corticosteroids are derived from natural adrenal cortisol or hydrocortisone. They are used because of their anti inflammatory benefits as well as the ability of some to inhibit mitotic divisions and to halt DNA synthesis. These compounds include, Prednisone, Dexamethasone, Methylprednisolone, and Prednisolone.

Hydroxyurea appears to act primarily through inhibition of the enzyme ribonucleotide reductase.

Asparagenase is an enzyme which converts asparagine to nonfunctional aspartic acid and thus blocks protein synthesis in the tumor.

The hormonal agents and leutinizing hormones are not usually used to substantially reduce the tumor mass. However, they can be used in conjunction with the chemotherapeutic agents or the herbicidal or fungicidal agents.

Hormonal blocking agents are also useful in the treatment of cancers and tumors. They are used in hormonally susceptible tumors and are usually derived from natural sources. These include:

estrogens, conjugated estrogens and Ethinyl Estradiol and Diethylstilbesterol, Chlorotrianisene and Idenestrol;

progestins such as Hydroxyprogesterone caproate, Medroxyprogesterone, and Megestrol;

androgens such as testosterone, testosterone propionate; fluoxymesterone, methyltestosterone;

Leutinizing hormone releasing hormone agents or gonadotropin-releasing hormone antagonists are used primarily the treatment of prostate cancer. These include leuprolide acetate and goserelin acetate. They prevent the biosynthesis of steroids in the testes.

Antihormonal antigens include:

antiestrogenic agents such as Tamosifen,

antiandrogen agents such as Flutamide ; and

antiadrenal agents such as Mitotane and Aminoglutethimide.

#### E. POTENTIATORS

The "potentiators" can be any material which improves or increases the efficacy of the pharmaceutical composition and/or act on the immune system. One such potentiator is triprolidine and its cis-isomer which are used in combination with the chemotherapeutic agents and the fungicide or herbicide. Triprolidine is described in US 5,114,951 (1992). Another potentiator is procodazole, 1H-Benzimidazole-2-propanoic acid; [ $\beta$ -(2-benzimidazole) propionic acid; 2-(2-carboxyethyl)benzimidazole; propazol) Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections and can be used with the compositions claimed herein.

The potentiators can improve the efficacy of the herbicidal or fungicidal compounds and can be used in a safe and effective amount. These combinations can be administered to the patient or animal by oral, rectal, topical or parenteral administration.

Antioxidant vitamins such as ascorbic acid, beta-carotene, vitamin A and vitamin E can be administered with the compositions of this invention.

#### F. DOSAGE

Any suitable dosage may be given in the method of the invention. The type of compound and the carrier and the amount will vary widely depending on the species of the warm blooded animal or human, body weight, and tumor being treated. Generally a dosage of as little as about 2 milligrams (mg) per kilogram (kg) of body weight and to as much as about 4000 mg per kg of body weight is suitable. Preferably from 15 mg to as much as about 1500 mg/kg of body weight is used. For the chemotherapeutic agents, a lower dosage may be appropriate, i.e., from about 0.01 mg/kg of body weight to about 400 mg/kg body weight, although amounts up to

1500 mg/kg can be used. Any suitable dosage can be given in the method of the invention for treating HIV. The type of compounds and the carriers and the amount will vary widely depending on the species of the warm blooded animal or human, body weight. The range and ratio of the fungicidal or herbicidal agents and their derivatives and the HIV treating agent used will depend on the type of agent. Generally, for the herbicidal or fungicidal agents and their derivatives a dosage of as little as about 2 milligrams (mg) per kilogram (kg) of body weight to as much as about 4000 mg per kg of body weight is suitable. Higher dosages, up to 6000 mg/kg can also be used. Preferably from 15 mg to as high a level as about 3000 mg/kg of body weight is used for the herbicidal or fungicidal agents. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. For the HIV agents from about 0.01 mg/kg to as much as 1500 mg/kg can be used. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. The dosage unit can also comprise diluents, extenders, carriers and the like. The unit may be in solid or gel form such as pills, tablets, capsules and the like or in liquid form suitable for oral, rectal, topical, intravenous injection or parenteral administration or injection into or around the tumor.

#### G. DOSAGE DELIVERY FORMS

The anti-cancer compounds are typically mixed with a pharmaceutically acceptable carrier. This carrier can be a solid or liquid and the type is generally chosen based on the type of administration being used. The active agent can be coadministered in the form of a tablet or capsule, as an agglomerated powder or in a liquid form. Examples of suitable solid carriers include lactose, sucrose, gelatin and agar. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Examples of suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents. Oral dosage forms optionally contain flavorants and

coloring agents. Parenteral and intravenous forms would also include minerals and other materials to make them compatible with the type of injection or delivery system chosen.

Specific examples of pharmaceutical acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in US. Pat. No. 3,903,297 to Robert, issued Sept. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976).

#### H. METHOD OF TREATMENT

The method of treatment can be any suitable method which is effective in the treatment of the particular virus, cancer or tumor type that is being treated. Treatment may be oral, rectal, topical, parenteral or intravenous administration or by injection into the tumor and the like. The method of applying or administering an effective amount also varies depending on the tumor or virus being treated. It is believed that parenteral treatment by intravenous, subcutaneous, or intramuscular application of the benzimidazole derivatives formulated with an appropriate carrier. Additional anti-viral materials can be used along with the benzimidazoles derivatives as well as additional cancer inhibiting compound(s) can be combined in the cancer treatments. Diluents can be used to facilitate application or administration is the preferred method of administering the compounds to warm blooded animals.

For the treatment of viral infections, the benzimidazole derivative is administered in doses for 7 to about 21 days or longer if needed to inhibit the growth or to kill the virus. In the case of chronic infections, these agents may need to be given for extended periods of time, up to years.

For the treatment of acute viral infections or HIV, the benzimidazole derivative can be administered after an AZT treatment or in conjunction with other HIV therapies. These drugs can be also administered in a sequential regimen in which the HIV virus is first reduced in the body and then the benzimidazole derivative is administered to keep the virus from continuing to replicate. AZT therapy can be continued during the treatment with the benzimidazole derivatives treatment. If the disease is in the early stages, the benzimidazole derivatives can be administered to keep the virus from replicating or growing and thus slow the progress of the disease.

In cancer treatments, preferably, the benzimidazole derivative is administered first to significantly reduce the size of the cancer or tumor mass. Usually this will take 3 to about 14 days. The reduction in the tumor or level of cancer cells will be to less than 50% of the original level. Radiation therapy may be used in conjunction with benzimidazole derivatives agent treatment.


Once the tumor has been reduced, the benzimidazole derivative is administered. Because of the relative safety of this material, it can be administered for from 14 days to 365 days as needed to maintain its effectiveness in reducing the regrowth of the cancer.

The following examples are illustrative and are not meant to be limiting to the invention.

#### Example 1


Each of the following compounds was tested for solubility, growth inhibition in a MTT assay against B16 Murine Melanoma and HT29, reported as  $IC_{50}(\mu M)$ , tubulin polymerization inhibition and indirect binding with calf thymus DNA using a Methyl Green displacement. The following results were achieved:

Compound Tested:



Estimated logP solubility	1.46 $\pm$ 0.60	
Growth Inhibitory Activity (MTT Assay)	Cell Line	$IC_{50}(\mu M)$
	B16 (Murine Melanoma)	4.925
	HT29 (Human Colon Carcinoma)	3.297

Compound tested:




Estimated logP solubility	1.99 $\pm$ 0.89	
Growth Inhibitory Activity (MTT Assay)	Cell Line	$IC_{50}(\mu M)$
	B16 (Murine Melanoma)	0.0844




HT29 (Human Colon  
Carcinoma) 0.266

Compound tested:




Estimated logP solubility	2.93 ± 0.86	
Growth Inhibitory	Cell Line	IC <sub>50</sub> (μM)
Activity (MTT Assay)		
	B16 (Murine Melanoma)	0.112
	HT29 (Human Colon Carcinoma)	0.102

Compound Tested:



Estimated logP solubility	2.72 ± 0.86	
Growth Inhibitory	Cell Line	IC <sub>50</sub> (μM)
Activity (MTT Assay)		
	B16 (Murine Melanoma)	0.0440
	HT29 (Human Colon Carcinoma)	0.00786


Compound Tested:



Estimated logP solubility	5.54 ± 0.87	
Growth Inhibitory	Cell Line	IC <sub>50</sub> (μM)
Activity (MTT Assay)		
	B16 (Murine Melanoma)	0.0769

14


Compound Tested:



Estimated logP solubility 4.61±0.86

Growth Inhibitory	Cell Line	IC <sub>50</sub> (μM)
Activity (MTT Assay)	B16 (Murine Melanoma)	0.0046

Compound Tested:




Estimated logP solubility 2.69±0.85

Growth Inhibitory	Cell Line	IC <sub>50</sub> (μM)
Activity (MTT Assay)	B16 (Murine Melanoma)	0.0621

Compound Tested:

## Claims :


1. A pharmaceutical composition for treating cancers, tumors or viral infections comprising a safe and effective amount of a benzimidazole derivative having the formula:




wherein R is selected from the group consisting of H, carboxyl ( $-\text{CO}_2\text{H}$ ), hydroxyl, amino or esters ( $-\text{CO}_2\text{R}'$ ) wherein  $\text{R}'$  is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1 - 8 carbons or  $\text{CH}_3\text{CH}_2(\text{OCH}_2\text{CH}_2)_n-$  or  $\text{CH}_3\text{CH}_2\text{CH}_2(\text{OCH}_2\text{CH}_2\text{CH}_2)_n-$  or  $(\text{CH}_3)_2\text{CH}-(\text{OCH}(\text{CH}_3)\text{CH}_2)_n-$  wherein n is from 1-3, or the pharmaceutically effective organic or inorganic salts thereof, or mixtures thereof.

2. A pharmaceutical composition according to Claim 1 comprising a pharmaceutically acceptable carrier and a safe and effective amount of a benzimidazole derivative.

3. A pharmaceutical composition according to Claim 2 wherein said benzimidazole derivative has the formula:




4. A pharmaceutical composition according to Claim 2 wherein said benzimidazole derivative is




**THIS PAGE BLANK (USPTO)**


5. A pharmaceutical composition according to Claim 2 wherein said benzimidazole derivative is




6. A pharmaceutical composition according to Claim 2 wherein said benzimidazole derivative is



7. A pharmaceutical composition according to Claim 2 wherein said benzimidazole derivative is



8. A pharmaceutical composition according to Claim 2 wherein said benzimidazole derivative is



**THIS PAGE BLANK (USPTO)**

9. A pharmaceutical composition according to Claim 1,2,3,4,5,6,7 or 8 wherein said pharmaceutical acceptable acid addition salts are selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates and mixtures thereof.
10. A method of treating viral infections in warm blooded mammals comprising administering a safe and effective amount of pharmaceutical composition according to claims 1,2,3,4,5,6,7,8 or 9.
11. A method for treating cancers or tumors comprising administering a safe and effective amount of a pharmaceutical composition according to claims 1,2,3,4,5,6,7,8 or 9.
12. A method according to Claim 11 wherein a chemotherapeutic agent is administered with the pharmaceutical composition.

**THIS PAGE BLANK (USPTO)**



(6643) WO 98/51304

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/21565

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 32107 A (THE PROCTER & GAMBLE COMPANY) 17 October 1996 see claims 1-16	1,2,9-12
Y	SIYA RAM ET AL.: "Synthesis and biological activity of certain alkyl 5-(alkoxycarbonyl)-1H-benzimidazol-2-carbamates and related derivatives: a new class of potential antineoplastic and antifilarial agents" J.MED.CHEM., vol. 35, 1995, pages 539-547, XP002056332 see abstract see page 543, left-hand column; table I -/--	1,2,9-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

19 February 1998

Date of mailing of the international search report

24.04.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Tzschoppe, D

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

Interr: ial Application No

PCT/US 97/21565

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ERNEST LACEY ET AL.: "Activity of benzimidazole carbamates against L1210 mouse leukemia cells: correlation with in vitro tubulin polymerization assay"</p> <p>BIOCHEM. PHARMACOL., vol. 34, no. 19, 1985, pages 3603-3605, XP002056333 see figure 1; table 1</p> <p>-----</p>	1,2,9-12

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 21565

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

SEE SEPARATE SHEET

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-2, 9-12

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**

FURTHER INFORMATION CONTINUED FROM PCT/ISA/

1. Claims: 1,2 and 9-12 (partly,  
in so far as the compositions of Claims 1 and 2 are concerned)

Pharmaceutical compositions containing benzimidazoles and methods of treating viral infections and cancers

2. Claims: 3 and 9-12 (partly,  
in so far as the composition of claim 3 is concerned)

Pharmaceutical composition containing the compound of Claim 3

3. Claims: 4 and 9-12 (partly,  
in so far as the composition of claim 4 is concerned)

Pharmaceutical composition containing the compound of Claim 4

4. Claims: 5 and 9-12 (partly,  
in so far as the composition of claim 5 is concerned)

Pharmaceutical composition containing the compound of Claim 5

5. Claims: 6 and 9-12 (partly,  
in so far as the composition of claim 6 is concerned)

Pharmaceutical composition containing the compound of Claim 6

6. Claims: 7 and 9-12 (partly,  
in so far as the composition of claim 7 is concerned)

Pharmaceutical composition containing the compound of Claim 7

7. Claims: 8 and 9-12 (partly,  
in so far as the composition of claim 8 is concerned)

**THIS PAGE BLANK (USP)**



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: al Application No

PCT/US 97/21565

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9632107 A	17-10-96	AU 5389796 A	30-10-96
		EP 0821586 A	04-02-98
		NO 974695 A	08-12-97
		AU 5802096 A	30-12-96
		EP 0831816 A	01-04-98
		NO 975660 A	09-02-98
		WO 9640122 A	19-12-96
-----			

**THIS PAGE BLANK (USPTO)**